Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months To evaluate the immunogenicity of two 0.25 mL IM doses of Fluad or Fluzone influenza vaccines in terms of post-vaccination geometric mean titers (GMTs), seroprotection rates and seroconversion rates, ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9 The present study, V72P9E1, is an extension of V72P9. The primary objective of this extension study will be to evaluate bactericidal antibody persistence at approximately 40 months of age in subjects ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Novartis Vaccine as Infants in Study V72P6 The present study, V72P6E1, is an extension of V72P6. The primary objective of this extension study will be to explore antibody persistence at approximately 40 months of age in subjects who received r...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Healthy Infants at 2, 4, 6 and/or 12 Months of Age To explore the immunogenicity of Novartis rMenB Vaccine +/- OMV-NZ when administered to healthy infants at 2, 4 and 6 months of age, at 30 days after the third dose, by evaluation of the breadth of ba...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune